Detalles de la búsqueda
1.
ProtEx technology for the generation of novel therapeutic cancer vaccines.
Exp Mol Pathol
; 86(3): 198-207, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19454266
2.
Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.
Curr Opin Investig Drugs
; 8(12): 1002-8, 2007 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-18058571
3.
SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ.
PLoS One
; 7(8): e42459, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22870329
4.
SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.
Vaccine
; 28(36): 5794-802, 2010 Aug 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-20603135
5.
4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.
Cancer Res
; 70(10): 3945-54, 2010 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20406989
6.
Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.
Cancer Res
; 69(10): 4319-26, 2009 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19435920
7.
A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.
Vaccine
; 28(2): 512-22, 2009 Dec 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-19836479
8.
Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling.
J Immunol
; 179(11): 7295-304, 2007 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18025172
Resultados
1 -
8
de 8
1
Próxima >
>>